Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

JTO clinical and research reports·2026

Same author

Endomyocardial Biopsy in Suspected Immune Checkpoint Inhibitor-Myocarditis: Histologic Spectrum and Correlations With Clinical and Cardiac Magnetic Resonance Features.

Journal of the American Heart Association·2026

Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026

Same author

High-Throughput Geocoding to Assess Short-Term Air Pollution in Correlation With Mortality in a French Cancer Patient Cohort.

International journal of cancer·2026

Same author

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

Cancer medicine·2026

Same author

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Oncology and therapy·2026

Search research articles

Related Experiment Video

Updated: Mar 9, 2026

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

Systemic treatment for thymic malignancies.

Nicolas Girard¹, Claire Merveilleux du Vignaux

¹aDepartment of Respiratory Medicine, National Expert Centre for Thymic Malignancies, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon bDepartment of Medical Oncology, Institut Curie cInstitut du Thorax Curie-Montsouris, Institut Curie, Institut Mutualiste Montsouris, Paris, France.

Current Opinion in Oncology

|December 28, 2016

Summary

Management of thymic epithelial tumors involves multidisciplinary collaboration. New treatments for advanced or recurrent thymic cancers include chemotherapy, angiogenesis inhibitors, and emerging immunotherapies, improving patient outcomes.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Related Experiment Videos

Last Updated: Mar 9, 2026

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Isolation and Transplantation of Different Aged Murine Thymic Grafts.

Published on: May 13, 2015

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Area of Science:

Oncology
Thoracic Surgery
Medical Research

Background:

Thymic epithelial tumors (TETs) require a multidisciplinary approach for effective management.
Chemotherapy is a key component, used in curative-intent strategies or as a standalone treatment when local therapies are not feasible.
Management of recurrent TETs mirrors strategies for newly diagnosed cases.

Purpose of the Study:

To review recent advancements in the management of thymic epithelial tumors.
To highlight novel therapeutic options for advanced, refractory, and recurrent TETs.
To discuss the evolving landscape of TET treatment strategies.

Main Methods:

Review of current literature on thymic epithelial tumor management.
Analysis of recent clinical trial data and therapeutic outcomes.
Assessment of emerging treatment modalities, including targeted therapies and immunotherapies.

Main Results:

Advanced treatment options for TETs now include cytotoxic agents (e.g., carboplatin-paclitaxel, pemetrexed, oral etoposide).
Angiogenesis inhibitors, such as sunitinib, are established in advanced-stage treatment.
Immunotherapy targeting programmed death-1/programmed death ligand-1 shows promise but carries risks of autoimmunity.

Conclusions:

Significant progress has been made in understanding and managing TETs, driven by research and clinical trials.
Despite challenges in drug approval due to tumor rarity, patient-centered initiatives and networks are crucial.
Continued research and collaborative efforts are essential for further improving TET patient care.